Abstract: Small liquid droplets, coated with protein, the protein coating containing molecules of protein that will interact specifically with a select protein, are contacted with a liquid sample to determine the presence or absence of the select protein therein depending upon whether the droplets agglutinate.
Type:
Grant
Filed:
October 29, 1984
Date of Patent:
October 28, 1986
Assignees:
General Electric Company, National Foundation for Cancer Research, Inc.
Abstract: Compositions containing compounds which exhibit immunomodulatory properties can be used as immunostimulants or immunosuppressants in humans and animals.
Type:
Grant
Filed:
September 29, 1983
Date of Patent:
May 21, 1985
Assignee:
National Foundation for Cancer Research, Inc.
Abstract: Novel condensation products between enediol ketolactones such as 5,6-0-isopropylidene ascorbic acid and 2-chloroethyl isocyanates are shown to have potent antitumor activity probably without the release of alkylating agents in vivo. While the structures of the products are not readily elucidated, activity is found to exceed that of BCNU (bis-(2-chloroethyl)-N-nitrosourea) and parallel that of the toxic and highly effective nitrosourea, MeCCNU (1-(4-trans-methylcyclohexyl)-3-(2-chloroethyl)-3-nitrosourea). Preferred compounds are condensation products of ##STR1## wherein R.sub.2 and R.sub.3 are a lower alkyl group containing 1 to 3 carbon atoms or H andhal--CH.sub.2 --CH.sub.2 --N.dbd.C.dbd.O (B)wherein hal is I, Br or Cl.
Type:
Grant
Filed:
October 23, 1981
Date of Patent:
December 27, 1983
Assignee:
National Foundation for Cancer Research, Inc.
Abstract: 1-Branched-alkyl-3-(2-haloethyl)-3-nitrosoureas which exhibit antitumor activity. Pharamaceutical compositions containing these novel compounds and methods of using them are also disclosed.
Type:
Grant
Filed:
August 8, 1979
Date of Patent:
December 27, 1983
Assignee:
National Foundation for Cancer Research, Inc.